Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > lets sell ATE

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on Mar 11, 2021 10:53am

137 Views

Post# 32772247

RE:RE:lets sell ATE

I used to love ATE so much but not anymore. So much corruption from dan, wallace and their d*mb deals. Basically they are stealing money from retail investors to benifit cannacord and themselves.

<< Previous

Bullboard Posts

Next >>

The top 5 Canadian small-cap AI stocks